Posted inBiotechnology
GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair
GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E (IgE) antibody to protect against food allergy reactions.…









